GRM5: Metabotropic glutamate receptor 5
G protein-coupled receptor for glutamate.
- Drugs that act on it: 9
- Approved: 0
- In phases 1 to 3: 9
- Sponsors: 6
Who is on it, and how far along
Every drug ChEMBL records acting on GRM5, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 7
- Other 2
Approved0
Phase 30
Phase 28
Phase 11
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Addex Pharma S.A.222%
- AstraZeneca Pharmaceuticals222%
- Eli Lilly111%
- Noema Pharma AG111%
- Novartis Pharmaceuticals111%
- Seaside Therapeutics, Inc.111%
| Basimglurant | Phase 2 | Noema Pharma AG | Small molecule | Modulator | 1 |
| Mavoglurant | Phase 2 | Novartis Pharmaceuticals | Small molecule | AntagonistMetabotropic glutamate receptor 5 antagonist | 1 |
| AZD2066 | Phase 2 | AstraZeneca Pharmaceuticals | Small molecule | Modulator | 0 |
| AZD2516 | Phase 2 | AstraZeneca Pharmaceuticals | Other | Negative allosteric modulatorMetabotropic glutamate receptor 5 negative allosteric modulator | 0 |
| Dasolampanel etibutil | Phase 2 | Eli Lilly | Small molecule | AntagonistMetabotropic glutamate receptor 5 antagonist | 0 |
| Dipraglurant | Phase 2 | Addex Pharma S.A. | Small molecule | Modulator | 0 |
| Raseglurant | Phase 2 | Addex Pharma S.A. | Small molecule | Modulator | 0 |
| STX107 | Phase 2 | Seaside Therapeutics, Inc. | Small molecule | Negative allosteric modulatorMetabotropic glutamate receptor 5 negative allosteric modulator | 0 |
| RG7342 | Phase 1 | — | Other | Modulator | 0 |
| Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers | Mavoglurant | Phase 1 | Recruiting | Yale University | Nov 18, 2023 |
| An Efficacy and Safety Study of Basimglurant (NOE-101) in Patients With Trigeminal Neuralgia. | Basimglurant | Phase 2 / Phase 3 | Active, not recruiting | Noema Pharma AG | Feb 1, 2022 |
- Major depressive disorder0.46
- Benign neoplasm of eye0.42
- Retinal detachment0.41
- Smoking initiation0.40
- Skin neoplasm0.39
- Cutaneous melanoma0.36
- Skin cancer0.36
- Autism spectrum disorder0.35
- Actinic keratosis0.35
- Alcohol drinking0.35
- Skin disorder0.34
- Skin reaction0.32
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3227, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P41594, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets